BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36853791)

  • 21. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
    Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
    Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
    Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
    J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.
    Arnett-Mansfield RL; deFazio A; Wain GV; Jaworski RC; Byth K; Mote PA; Clarke CL
    Cancer Res; 2001 Jun; 61(11):4576-82. PubMed ID: 11389093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
    Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
    Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical study of endometrial high-grade endometrioid carcinoma with or without a concurrent low-grade component: implications for pathogenetic and survival differences.
    Mao TL; Ayhan A; Kuo KT; Lin MC; Tseng LH; Ogawa H
    Histopathology; 2015 Oct; 67(4):474-82. PubMed ID: 25648330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular profiles of benign and (pre)malignant endometrial lesions.
    van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
    Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
    Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
    Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].
    Lax S
    Pathologe; 2011 Nov; 32 Suppl 2():255-64. PubMed ID: 22033684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
    Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
    Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
    Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
    Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
    Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
    Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance.
    Niskakoski A; Pasanen A; Lassus H; Renkonen-Sinisalo L; Kaur S; Mecklin JP; Bützow R; Peltomäki P
    Mod Pathol; 2018 Aug; 31(8):1291-1301. PubMed ID: 29588532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer.
    Jeong O; Broaddus RR; Lessey BA; Risinger JI; Hunter MI; Kim TH
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A loss activates MAPK signaling via DUSP4 downregulation.
    Mandal J; Yu ZC; Shih IM; Wang TL
    J Biomed Sci; 2023 Dec; 30(1):94. PubMed ID: 38071325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.